Innovative approaches in early-phase trials, such as the IDH1 Vaccine Trial (101), RNA-LPAs (46), and mRNA-based vaccines (16, 47, 49, 128), can potentially target specific tumor mutations and reprogram the tumor microenvironment. Here, IDH1 is linked to neoplasm.